Core Viewpoint - Company expects a net profit loss of 24 million to 35 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 24 million to 35 million yuan for 2025 after deducting non-recurring items [1] - The decline in profit is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to decreased product procurement prices from hospital clients and fluctuations in order volumes, which pose challenges to sales revenue and gross profit levels [2] - Despite cost-saving measures, fixed expenditures cannot be reduced proportionally to income, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investment, and expanding the market development team [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to the parent company was -12.39 million yuan, a year-on-year decline of 146.65% [3] - The gross profit margin stood at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - Company expects a net profit loss of 25 million to 36 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 25 million to 36 million yuan for 2025 [1] - The forecasted loss is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to a decrease in product procurement prices and fluctuations in order volumes, which pose challenges to sales revenue and gross margin [2] - Despite cost-saving measures, fixed expenditures remain constant, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is adjusting its business layout and strategy, focusing on the "ACME" proprietary products, increasing R&D investment, and expanding the market development team to enhance high-value services for hospital clients [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to shareholders was -12.39 million yuan, a decline of 146.65% year-on-year [3] - The gross margin was reported at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - The company, Hefei China, anticipates a significant net loss for the year 2025, with projected losses ranging from 25 million to 36 million yuan for net profit attributable to shareholders, and from 24 million to 35 million yuan for net profit after excluding non-recurring gains and losses [1] Group 1: Financial Performance - The expected net loss for 2025 is between 25 million and 36 million yuan [1] - The projected net profit after excluding non-recurring items is estimated to be between 24 million and 35 million yuan [1] Group 2: Reasons for Performance - The primary reasons for the anticipated losses include changes in the domestic macro environment and the impact of centralized procurement policies in the in-vitro diagnostic industry, leading to decreased product procurement prices and fluctuations in order volumes [1] - Despite cost-saving measures, fixed expenditures could not be proportionately reduced alongside income, and investments in talent optimization and capability upgrades contributed to the expected losses [1] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investments, and expanding its market development team [1]